Masashi Okamoto, Shoji Kawada, Hiroshi Shimagami, Naoko Fujii, Kazuki Matsukawa, Nachi Ishikawa, Keisuke Kawamoto, Shinji Higa, Yutaka Ishida, Atsushi Ogata, et al. Rapid attenuation of anti-SARS-CoV-2 antibodies in patients with musculoskeletal diseases in whom intensive immunosuppressive therapies were reinitiated after COVID-19: comment on the article by Curtis et al. Arthritis & rheumatology (Hoboken, N.J.). 2022. 74. 4. 726-728
Toshihiro Kishikawa, Yuichi Maeda, Takuro Nii, Noriko Arase, Jun Hirata, Ken Suzuki, Kenichi Yamamoto, Tatsuo Masuda, Kotaro Ogawa, Shigeyoshi Tsuji, et al. Increased levels of plasma nucleotides in patients with rheumatoid arthritis. International Immunology. 2021. 33. 2. 119-124
Ogata A, Tanaka Y, Ishii T, Kaneko M, Miwa H, Ohsawa S, Yamakawa R, SHINOBI Study Group. Long-Term Safety and Efficacy of Weekly Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to Subcutaneous Tocilizumab Every Other Week: Results From the Open-Label Extension of the SHINOBI Study. Modern rheumatology. 2018. 1-22
Toshihiro Kishikawa, Yuichi Maeda, Takuro Nii, Daisuke Motooka, Yuki Matsumoto, Masato Matsushita, Hidetoshi Matsuoka, Maiko Yoshimura, Shoji Kawada, Satoru Teshigawara, et al. Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. Annals of the rheumatic diseases. 2020. 79. 1. 103-111
Mark C. Genovese, Atsushi Ogata, Akira Nomura, Min Bao, Elena Hitraya, Stuart Lacey, Gerd R. Burmester. IMMUNOGENICITY OF SUBCUTANEOUS AND INTRAVENOUS TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS. RHEUMATOLOGY. 2016. 55. 92-93
Mark C. Genovese, Atsushi Ogata, Akira Nomura, Min Bao, Elena Hitraya, Stuart Lacey, Gerd Burmester. Immunogenicity of Subcutaneous and Intravenous Tocilizumab As Monotherapy or in Combination with Dmards. ARTHRITIS & RHEUMATOLOGY. 2015. 67
Y. Takahashi, M. Fujimoto, S. Serada, A. Ogata, T. Nanki, K. Hattori, T. Takeuchi, T. Naka. LEUCINE-RICH ALPHA-2 GLYCOPROTEIN (LRG) AS A POTENTIAL DISEASE ACTIVITY MARKER DURING IL-6 BLOCKADE IN AUTOIMMUNE ARTHRITIS. ANNALS OF THE RHEUMATIC DISEASES. 2015. 74. 1062-1062